Wang Jialu, Lu Yafang, Zhang Ren, Cai Zhenzhen, Fan Zhan, Xu Yilun, Liu Zheng, Zhang Zhihong
Britton Chance Center and MOE Key Laboratory for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics, Huazhong University of Science and Technology, Wuhan, 430074 Hubei China.
Key Laboratory of Biomedical Engineering of Hainan Province, School of Biomedical Engineering, Hainan University, Haikou, 570228 Hainan China.
Phenomics. 2024 Jun 22;4(4):401-414. doi: 10.1007/s43657-023-00154-6. eCollection 2024 Aug.
Cancer immunotherapy has made great progress in effectively attacking or eliminating cancer. However, the challenges posed by the low reactivity of some solid tumors still remain. Macrophages, as a key component of the tumor microenvironment (TME), play an important role in determining the progression of solid tumors due to their plasticity and heterogeneity. Targeting and reprogramming macrophages in TME to desired phenotypes offers an innovative and promising approach for cancer immunotherapy. Meanwhile, the rapid development of in vivo molecular imaging techniques provides us with powerful tools to study macrophages. In this review, we summarize the current progress in macrophage reprogramming from conceptual roadmaps to therapeutic approaches, including monoclonal antibody drugs, small molecule drugs, gene therapy, and chimeric antigen receptor-engineered macrophages (CAR-M). More importantly, we highlight the significance of molecular imaging in observing and understanding the process of macrophage reprogramming during cancer immunotherapy. Finally, we introduce the therapeutic applications of imaging and reprogramming macrophages in three solid tumors. In the future, the integration of molecular imaging into the development of novel macrophage reprogramming strategies holds great promise for precise clinical cancer immunotherapy.
癌症免疫疗法在有效攻击或消除癌症方面取得了巨大进展。然而,一些实体瘤反应性低所带来的挑战仍然存在。巨噬细胞作为肿瘤微环境(TME)的关键组成部分,由于其可塑性和异质性,在决定实体瘤的进展中起着重要作用。将TME中的巨噬细胞靶向并重编程为所需表型为癌症免疫疗法提供了一种创新且有前景的方法。同时,体内分子成像技术的快速发展为我们研究巨噬细胞提供了强大工具。在本综述中,我们总结了巨噬细胞重编程从概念路线图到治疗方法的当前进展,包括单克隆抗体药物、小分子药物、基因治疗和嵌合抗原受体工程化巨噬细胞(CAR-M)。更重要的是,我们强调了分子成像在观察和理解癌症免疫疗法期间巨噬细胞重编程过程中的重要性。最后,我们介绍了成像和重编程巨噬细胞在三种实体瘤中的治疗应用。未来,将分子成像整合到新型巨噬细胞重编程策略的开发中,对精确的临床癌症免疫疗法具有巨大的前景。